Philip J M Brouwer, Mitch Brinkkemper, Pauline Maisonnasse, Nathalie Dereuddre-Bosquet, Marloes Grobben, Mathieu Claireaux, Marlon de Gast, Romain Marlin, Virginie Chesnais, Ségolène Diry, Joel D Allen, Yasunori Watanabe, Julia M Giezen, Gius Kerster, Hannah L Turner, Karlijn van der Straten, Cynthia A van der Linden, Yoann Aldon, Thibaut Naninck, Ilja Bontjer, Judith A Burger, Meliawati Poniman, Anna Z Mykytyn, Nisreen M A Okba, Edith E Schermer, Marielle J van Breemen, Rashmi Ravichandran, Tom G Caniels, Jelle van Schooten, Nidhal Kahlaoui, Vanessa Contreras, Julien Lemaître, Catherine Chapon, Raphaël Ho Tsong Fang, Julien Villaudy, Kwinten Sliepen, Yme U van der Velden, Bart L Haagmans, Godelieve J de Bree, Eric Ginoux, Andrew B Ward, Max Crispin, Neil P King, Sylvie van der Werf, Marit J van Gils, Roger Le Grand, Rogier W Sanders
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission, and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits, and cynomolgus macaques...
March 4, 2021: Cell